US5776905A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Apoptotic regression of intimal vascular lesions
Assignee: Leland Stanford Junior University
•
Filing: 1996-08-08
•
Granted: 1998-07-07
•
Expires: 2016-08-08
Abstract
Abstract Neointimal cells are shown to express high levels of an anti-apoptotic gene, bcl-x, while the medial cells of the vessel itself express only low levels. The difference in gene expression exploited to provide for selective deletion of the neointimal cells. Apoptosis is induced by administering anti-sense bcl-x oligonucleotides to the affected vessel. Apoptosis is desirable as a treatment because it does not induce inflammation, further tissue injury or reactive hyperplasia. A significant reduction in lesion size is seen after treatment.
Inventors
- 👤 Gary H. Gibbons
- 👤 Matthew J. Pollman
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 22:43
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C12N15/113; C07; C07K; C07K14/00; C07K14/435; C07K14/46; C07K14/47; A; A61; A61K; A61K38/00; C12N2310/00; C12N2310/30; C12N2310/31; C12N2310/315
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
49 words
A method of reducing the dimensions of a neointimal vascular lesion in a patient, the method comprising: administering an effective amount of a synthetic anti-sense oligonucleotide that specifically blocks expression of bcl-x; wherein apoptosis is induced in said neointimal cells, thereby reducing the dimensions of said neointimal vascular lesion.
Claim 2
Independent Claim
49 words
A method of reducing the dimensions of a neointimal vascular lesion in a patient, the method comprising: administering an effective amount of a synthetic anti-sense oligonucleotide that specifically blocks expression of bcl-x; wherein apoptosis is induced in said neointimal cells, thereby reducing the dimensions of said neointimal vascular lesion.
Claim 3
Dependent Claim
15 words
A method according to claim 1, wherein said synthetic antisense oligonucleotide comprises a phosphorothioate backbone.
Claim 4
Dependent Claim
15 words
A method according to claim 1, wherein said antisense oligonucleotide is administered by pressure-mediated delivery.
Claim 5
Dependent Claim
15 words
A method according to claim 1, wherein said antisense oligonucleotide is administered by liposome delivery.
Claim 6
Dependent Claim
14 words
A method according to claim 1, wherein said neointimal hyperplasia is an athersclerotic lesion.
Claim 7
Dependent Claim
23 words
A method according to claim 1, wherein said synthetic antisense oligonucleotide is complementary to the region of the translation initiation codon of bcl-x.
Claim 8
Independent Claim
64 words
A method of reducing the dimensions of a neointimal vascular lesion in a patient, the method comprising: administering an effective amount of a synthetic anti-sense oligonucleotide that (a) specifically blocks expression of bcl-x; and (b) is complementary to the region of the translation initiation codon of bcl-x; wherein apoptosis is induced in said neointimal cells, thereby reducing the dimensions of said neointimal vascular lesion.
Claim 9
Independent Claim
64 words
A method of reducing the dimensions of a neointimal vascular lesion in a patient, the method comprising: administering an effective amount of a synthetic anti-sense oligonucleotide that (a) specifically blocks expression of bcl-x; and (b) is complementary to the region of the translation initiation codon of bcl-x; wherein apoptosis is induced in said neointimal cells, thereby reducing the dimensions of said neointimal vascular lesion.
Claim 10
Dependent Claim
15 words
A method according to claim 7, wherein said synthetic antisense oligonucleotide comprises a phosphorothioate backbone.
Claim 11
Dependent Claim
15 words
A method according to claim 7, wherein said antisense oligonucleotide is administered by pressure-mediated delivery.
Claim 12
Dependent Claim
15 words
A method according to claim 7, wherein said antisense oligonucleotide is administered by liposome delivery.
Claim 13
Dependent Claim
14 words
A method according to claim 7, wherein said neointimal hyperplasia is an athersclerotic lesion.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-07-06 | 2002-01-05 | 2002-07-07 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-07-06 | 2006-01-05 | 2006-07-07 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-07-06 | 2010-01-05 | 2010-07-07 | $7700.00 | Window Closed / Lapsed |